Potential antitumor agents. 36. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents
作者:William A. Denny、Bruce F. Cain、Graham J. Atwell、Corwin Hansch、Augustine Panthananickal、A. Leo
DOI:10.1021/jm00345a015
日期:1982.3
relationships (QSAR) have been derived between antileukemic (L1210) activity and agent physicochemical properties for 509 tumor-active members of the general class of 9-anilinoacridines. One member of this class is the clinical agent m-AMSA (NSC 249992). Agent hydrophobicity proved a significant but not a dominant influence on in vivo potency. The electronic properties of substituent groups proved important
[EN] CHEMOSELECTIVE THIOL-CONJUGATION WITH ALKENE OR ALKYNE-PHOSPHONAMIDATES<br/>[FR] CONJUGAISON CHIMIOSÉLECTIVE D'UN THIOL AVEC DES ALCÈNE- OU ALCYNE-PHOSPHONAMIDATES
申请人:FORSCHUNGSVERBUND BERLIN EV
公开号:WO2018041985A1
公开(公告)日:2018-03-08
Disclosed are novel conjugates and processes for the preparation thereof. A process for the preparation of alkene- or alkyne-phosphonamidates comprises the steps of (I) reacting a compound of formula (III), with an azide of formula (IV), to prepare a compound of formula (V), reacting a compound of formula (V) with a thiol-containing molecule of formula (VI), resulting in a compound of formula (VII).
[EN] INHIBITORS OF PRC1 FOR TREATMENT OF CANCER<br/>[FR] INHIBITEURS DE PRC1 POUR LE TRAITEMENT DU CANCER
申请人:UNIV TEXAS
公开号:WO2020264348A1
公开(公告)日:2020-12-30
Disclosed herein are compounds and methods for the inhibition of the RNF1 or RNF2 subunit of polycomb repressive complex 1 (PRC1) for the treatment of metastatic cancer, such as metastatic castration-resistant prostate cancer. The inhibitors can be combined with checkpoint inhibitors such as PD-1 inhibitors, PD-L1 inhibitors, or CTLA-4 inhibitors.
The invention is directed to pyrido[4,3-d]pyrimidin-5(6H)-one derivatives. Specifically, the invention is directed to compounds according to Formula I:
wherein R
1
, R
2
, R
3
, and R
4
are defined below.
The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.